Author(s):
Sanjesh G Rathi, Poonam S Yadav, Sohan S Vaghela, Shrenik S Shah
Email(s):
rathi.sanjesh@gmail.com
DOI:
10.52711/0974-360X.2022.00212 
Address:
Sanjesh G Rathi1*, Poonam S Yadav2, Sohan S Vaghela2, Shrenik S Shah2
1Department of Pharmaceutics, School of pharmacy, Rai University, Saroda, Dholka Road, Ahmedabad, 382260 Gujarat.
2Department of Pharmaceutics Saraswati Institute of Pharmaceutical Sciences, Dhanap - 382355, Gujarat.
*Corresponding Author
Published In:
Volume - 15,
Issue - 3,
Year - 2022
ABSTRACT:
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric fluids and thus remain buoyant in the stomach for a prolonged period of time, without affecting the gastric emptying rate. While the system is floating on the gastric contents, the drug is released slowly at a desired rate from the system. These floating tablets mainly prepared for reduction of lag time and release the drug up to 12 hours and may also increase the bioavailability of the drugs by utilizing the drug to full extent avoiding unnecessary frequency of dosing. The study included formulation of floating tablets using polymers like Hydroxypropylmethylcellulose K4M and Carbopol 934 as matrix forming agents. The tablets were directly compressed using multi station rotary punching machine. FTIR studies conformed that there was no incompatibility between the polymers and the drug. Tablet preformulation parameters were within the Pharmacopoeias limit. Tablet showed buoyancy for >12 h. The in- vitro drug release pattern of floating tablets was fitted to different kinetic models which showed highest regression for higuchi model. Formulation E6 found stable during 1 month stability study.
Cite this article:
Sanjesh G Rathi, Poonam S Yadav, Sohan S Vaghela, Shrenik S Shah. Formulation and Evaluation of Stomach Specific Floating Tablets of Eluxadoline. Research Journal of Pharmacy and Technology. 2022; 15(3):1267-2. doi: 10.52711/0974-360X.2022.00212
Cite(Electronic):
Sanjesh G Rathi, Poonam S Yadav, Sohan S Vaghela, Shrenik S Shah. Formulation and Evaluation of Stomach Specific Floating Tablets of Eluxadoline. Research Journal of Pharmacy and Technology. 2022; 15(3):1267-2. doi: 10.52711/0974-360X.2022.00212 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-3-55
REFERENCES:
1. Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics a treatise. 1st ed. Delhi: Vallabh Prakashan. 2003.
2. Jain NK. Pharmaceutical product development. 1st ed. Delhi: CBS Publication and Distribution. 2006.
3. Arora S, Ali J, Ahuja A, Khar R, Baboota S. Floating drug delivery systems: a review. AAPS Pharm Sci Tech, 2005, 06 (03), 1-8.
4. Yeole P, Khan S, Patel V, “Floating drug delivery system: need and development.” Ind J Pham Sci, 2005, 67(3), 265-271.
5. Shirwaikar A, Kumar S, Jacob S, Rashi W, Ravi K, “Recent development in floating drug delivery system for gastric retention of drugs, an overview.” Ind Drugs, 2006, 43(9), 697-703.
6. Talukder R, Fassihi R. “Gastroretentive delivery system: A mini review.” Drug Dev Ind Pharm, 2004, 30(10), 1019-28.
7. Jain S, Jain N, Agrawal G, “Gastroretentive floating drug delivery: An overview.” Drug Delivery Tech, 2005, 5(7), 1-9.
8. Garg S, Sharma S. “Gastroretentive drug delivery system, Business Briefing,” Drug Delivery Oral, Pharmtech, 2003, 160-66.
9. Singh B, Kim K. “Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention.” J Con Rel, 2000, 63, 235-59.
10. Disease Information, October 2019: - https://www.mayoclinic.org/diseases-conditions/ irritable-bowel
11. Drug Information, October 2019:- https://www.drugbank.ca/drugs/DB09272, Oct, 2018.
12. Drug Information, October 2019:- https://pubchem.ncbi.nlm.nih.gov/compound/Eluxadoline, Oct, 2018.
13. Drug Information, October 2019:- https://www.rxlist.com/viberzi-drug.htm#indications, Oct, 2018.
14. Rowe, Raymond C., Paul J. Sheskey and Paul J. Weller. 2003. Handbook of pharmaceutical excipients. London: Pharmaceutical Press.